Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO MINASTRIN FE vs DEMULEN 1/50-21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, inhibiting sperm penetration; alters endometrial lining, reducing implantation likelihood.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years of age who have no known contraindications, desire oral contraception, and have achieved menarche
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label use)
1 tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol/ferrous fumarate 75 mg) orally once daily for 28 consecutive days.
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
Norethindrone: 8-11 hours; ethinyl estradiol: 12-16 hours. Steady-state achieved after 5-7 days of dosing.
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Hepatic via CYP3A4 (ethinyl estradiol) and primarily reduction and conjugation (norethindrone); undergoes first-pass metabolism.
Ethinyl estradiol undergoes first-pass metabolism in the gut wall and liver, with hydroxylation by CYP3A4 and conjugation via glucuronidation and sulfation. Ethynodiol diacetate is rapidly deacetylated to norethindrone, which is metabolized by reduction and conjugation, with CYP3A4 as a minor pathway.
Renal: 40-50% as conjugated metabolites; fecal: 20-30% via biliary excretion; unchanged drug <1%.
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
Norethindrone: 97% bound (primarily to albumin and SHBG); ethinyl estradiol: 98% bound (primarily to albumin).
Ethinylestradiol: 97-98% bound to serum albumin (primarily) and SHBG; ethynodiol diacetate: >95% bound to albumin and SHBG.
Norethindrone: 4 L/kg; ethinyl estradiol: 2-4 L/kg; reflects extensive tissue distribution and binding to sex hormone receptors.
Ethinylestradiol: 2.8-4.3 L/kg (extensive tissue distribution, including breast and reproductive tissues); ethynodiol: 1.5-2.0 L/kg.
Oral: norethindrone ~64%, ethinyl estradiol ~40-48% due to first-pass metabolism.
Oral: Ethinylestradiol 38-48% (first-pass metabolism); ethynodiol diacetate ~60% (rapid hydrolysis to active norethindrone).
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Contraindicated in severe renal impairment (GFR <30 m L/min) or acute renal failure due to potential for hyperkalemia from ferrous fumarate.
No dose adjustment required for mild-moderate renal impairment. Avoid use in severe renal impairment or dialysis due to potential fluid retention and electrolyte disturbances.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, use caution; consider lower dose estrogen combination if necessary.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Use in mild hepatic impairment not recommended.
Not indicated for use prepubertal. Approved for females of reproductive potential; safety and efficacy in children <12 years not established. Follow adult dosing postmenarche.
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults. Safety and efficacy established in post-pubertal females.
Not indicated for use in postmenopausal women. In women >35 years who smoke, use is contraindicated due to increased cardiovascular risk.
Not indicated after menopause. Risk of thromboembolic events outweighs benefits in women over 35 who smoke or have cardiovascular risk factors.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (>35 years) and with heavy smoking (≥15 cigarettes/day). Women >35 years who smoke should not use combination oral contraceptives.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebrovascular accidents, myocardial infarction),Hepatic disease (benign/malignant tumors),Hypertension,Gallbladder disease,Carbohydrate/lipid metabolism effects,Ocular changes (retinal thrombosis),Headache/migraine,Uterine bleeding irregularities,Depression,Cervical cancer screening,Pregnancy test prior to initiation,Lactation (possible decreased milk production)
Increased risk of thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking increases cardiovascular risk, especially in women over 35,Increased risk of hypertension, gallbladder disease, and hepatic neoplasia,Risk of retinal thrombosis; discontinue if unexplained vision loss occurs,May cause fluid retention; use with caution in conditions affected by fluid retention,May induce cholestatic jaundice; discontinue if jaundice develops,May cause carbohydrate and lipid metabolism changes
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Carcinoma of endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (>15 cigarettes/day) in women >35 years
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma,Active liver disease (e.g., acute viral hepatitis, decompensated cirrhosis),Hypersensitivity to any component
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels, but clinical significance is minimal. Avoid alcohol if liver function is compromised. Iron absorption from ferrous fumarate is enhanced by vitamin C, but not clinically important.
No specific food interactions. Oral contraceptives may increase caffeine levels; limit caffeine intake if side effects like jitteriness occur. Grapefruit and grapefruit juice do not significantly affect this medication.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester use associated with cardiovascular defects, neural tube defects; second/third trimester use associated with fetal genital changes, hepatic adenoma.
First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Second and third trimesters: Avoid due to risk of fetal harm, including masculinization of female fetus with progestins; also associated with increased risk of neonatal jaundice and liver dysfunction.
Excreted in breast milk in small amounts (M/P ratio ~0.5). No adverse effects reported in infants, but may reduce milk production. Use with caution.
Small amounts of ethinyl estradiol and ethynodiol diacetate are excreted in breast milk. M/P ratio not established. Estrogen-progestin combinations may reduce milk production and alter milk composition; use during breastfeeding is generally not recommended. Consider alternative contraception.
No dose adjustment indicated as drug is contraindicated in pregnancy.
Not applicable as use is contraindicated during pregnancy. No pharmacokinetic studies have been conducted to recommend dose adjustments.
LO MINASTRIN FE is a low-dose combination oral contraceptive (1 mg norethindrone acetate / 20 mcg ethinyl estradiol) with ferrous fumarate tablets. It is indicated for contraception and may improve menstrual regularity. The iron component is not bioavailable during active hormone intake; iron tablets are placebo-day supplements. Monitor for thromboembolic risks, especially in smokers over 35. Breakthrough bleeding is common in the first few cycles. Do not use in hepatic disease or known pregnancy.
DEMULEN 1/50-21 is a monophasic oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Use with caution in patients over 35 who smoke due to increased cardiovascular risk. Monitor for breakthrough bleeding, especially in the first three cycles. Consider drug interactions with rifampin, anticonvulsants, and broad-spectrum antibiotics. Administer at the same time daily to maintain efficacy. The 21-day regimen requires a 7-day pill-free interval. Instruct to start on first day of menses or first Sunday after onset.
Take one tablet daily at the same time; the last 7 tablets contain iron instead of hormones.,Missed dose: if missed within 12 hours, take it as soon as remembered; if more than 12 hours, skip the missed dose and continue schedule; use back-up contraception for 7 days.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35 years old.,Inform your healthcare provider of any new onset headaches, chest pain, leg pain/swelling, or visual disturbances.,Breakthrough bleeding is common initially; if persistent, consult your doctor.,Use additional non-hormonal contraception during first 7 days of starting the pill.,Store at room temperature; keep out of reach of children; iron tablets may be harmful to children if ingested.
Take one tablet daily at the same time, starting on the first day of your menstrual period or the first Sunday after your period begins.,Swallow tablet whole with water, with or without food.,After finishing all 21 tablets, wait 7 days before starting a new pack. You will have a withdrawal bleed during this time.,If you miss a tablet by less than 12 hours, take it immediately. If more than 12 hours, take the missed tablet and use backup contraception for 7 days.,Seek emergency medical care for symptoms of blood clots (sudden severe headache, chest pain, shortness of breath, leg pain/swelling), stroke (sudden numbness/weakness, slurred speech), or liver problems (yellowing skin/eyes, dark urine).,Avoid smoking while taking this medication, especially if over age 35, due to increased risk of cardiovascular events.,Inform your healthcare provider about all other medications (including over-the-counter drugs, herbal supplements like St. John's Wort) as they may reduce contraceptive efficacy.,This medication does not protect against HIV or other sexually transmitted infections.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO MINASTRIN FE vs DEMULEN 1/50-21, answered by our medical review team.
LO MINASTRIN FE is a Combination Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, inhibiting sperm penetration; alters endometrial lining, reducing implantation likelihood.. DEMULEN 1/50-21 is a Combination Oral Contraceptive that works by DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO MINASTRIN FE and DEMULEN 1/50-21 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO MINASTRIN FE is: 1 tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol/ferrous fumarate 75 mg) orally once daily for 28 consecutive days.. The standard adult dose of DEMULEN 1/50-21 is: 1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO MINASTRIN FE and DEMULEN 1/50-21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO MINASTRIN FE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester use associated with cardiovascular defects, neural tube defects; second/third trimeste. DEMULEN 1/50-21 is classified as Category C. First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.